What TB Treatment advocates need to Know about active TB Drug Safety Monitoring and Management and Pharmacovigilance?
This webinar was brought by Treatment Action Group (TAG) to provide TB advocates, people with TB, and community treatment supporters with the basics of monitoring and management of newer TB treatments, identifying common side effects, and recognizing patient safety during treatment. This webinar is part of Unitaid-funded and KNCV-led ASCENT DR-TB Project.
Treatment Action Group (TAG) hosted the webinar “What TB Treatment advocates need to Know about active TB Drug Safety Monitoring and Management and Pharmacovigilance (aDSM/PV)” on Tuesday, April 16.
Why this webinar matters?
In recent years, a new generation of shorter, all-oral, and effective medicines for drug-resistant tuberculosis (DR-TB) has been recommended by the World Health Organization (WHO). These alternative regimens, which are referred to as BPaL/M, BEAT, and endTB, are shorter and easier on patients than previous drug regimens that include multiple drugs with harsh side effects. However, newer forms of care require close attention to adverse side effects and harmful responses – also known as pharmacovigilance.
The webinar provided TB advocates, people with TB, and community treatment supporters with the basics of monitoring and management of newer TB treatments, identifying common side effects, and recognizing patient safety during treatment.
Webinar details:
- This webinar was conducted on April 16, 2026.
Experts
Moderator:
- Mike Frick (TAG)
Presenters:
- Nathalie Lachenal (Médecins Sans Frontières)
- Mansa Mbenga (KNCV)
